Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Pasritamig |
Trade Name | |
Synonyms | JNJ78278343|JNJ 78278343|JNJ-78278343 |
Drug Descriptions |
Pasritamig (JNJ-78278343) is an IgG1 bispecific antibody that targets KLK2 on tumor cells and CD3 on T-lymphocytes, which may lead to T-lymphocyte activation and killing of tumor cells expressing KLK2 (PMID: 40450573). |
DrugClasses | CD3 Antibody 115 |
CAS Registry Number | NA |
NCIT ID | C180825 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cetrelimab + Pasritamig | Cetrelimab Pasritamig | 0 | 1 |
JNJ-87189401 + Pasritamig | JNJ-87189401 Pasritamig | 0 | 1 |
Pasritamig | Pasritamig | 0 | 1 |